DB
EVH icon

Danske Bank’s Evolent Health EVH Stock Holding History

Danske Bank’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$400 – 1303
2025
Q4 		$400 Hold
100
– – ﹤0.01% 1428
2025
Q3 		$846 Hold
100
– – ﹤0.01% 1381
2025
Q2 		$1.13K Hold
100
– – ﹤0.01% 1418
2025
Q1 		$947 Hold
100
– – ﹤0.01% 1274
2024
Q4 		$1.13K Sell
100
-30,131
-100% -$530K ﹤0.01% 1291
2024
Q3 		$855K Buy
+30,231
New +$779K ﹤0.01% 839

Other funds holding EVH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Danske Bank's EVH Position: Q1 2026 in Review

Danske Bank sold out of Evolent Health (EVH) in Q1 2026, closing a stake of 100 shares — an estimated $400 sold.

Danske Bank first reported a position in EVH in Q3 2024 and held it in 6 quarters. The position peaked at $855K in Q3 2024. 192 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Danske Bank reported no remaining Evolent Health position as of Q1 2026 after selling out during the quarter.
  • Danske Bank sold 100 Evolent Health shares in Q1 2026, an estimated $400.
  • Danske Bank first reported a position in Evolent Health in Q3 2024 and held it in 6 quarters.
  • Danske Bank's Evolent Health position peaked at $855K in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.